Mitsubishi UFJ Trust & Banking Corp Has $14.90 Million Stock Holdings in Guardant Health, Inc. $GH

Mitsubishi UFJ Trust & Banking Corp decreased its position in Guardant Health, Inc. (NASDAQ:GH) by 18.2% during the 4th quarter, Holdings Channel reports. The firm owned 145,885 shares of the company’s stock after selling 32,424 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Guardant Health were worth $14,901,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Guardant Health by 6.6% in the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock valued at $320,378,000 after acquiring an additional 317,906 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Guardant Health by 26.1% in the third quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after acquiring an additional 606,368 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Guardant Health in the 3rd quarter worth approximately $114,421,000. Finally, Federated Hermes Inc. boosted its holdings in shares of Guardant Health by 21.2% in the 3rd quarter. Federated Hermes Inc. now owns 1,776,369 shares of the company’s stock worth $110,988,000 after acquiring an additional 310,931 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on GH. Guggenheim raised their price target on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Piper Sandler increased their target price on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, February 24th. Wells Fargo & Company lifted their price target on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Stifel Nicolaus increased their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, TD Cowen raised their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.63.

Guardant Health Stock Up 4.4%

Shares of GH stock opened at $87.08 on Friday. The stock has a 50-day moving average price of $89.30 and a 200 day moving average price of $95.91. The firm has a market cap of $11.54 billion, a price-to-earnings ratio of -26.31 and a beta of 1.64. Guardant Health, Inc. has a 12 month low of $36.36 and a 12 month high of $120.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. The company’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS. Sell-side analysts predict that Guardant Health, Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 1,300 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total value of $119,002.00. Following the transaction, the director directly owned 1,193 shares in the company, valued at $109,207.22. This represents a 52.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Musa Tariq sold 348 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32. Following the completion of the transaction, the director directly owned 8,394 shares in the company, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 8,596 shares of company stock valued at $775,767. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.